推荐产品
等级
certified reference material
质量水平
形式
liquid
特点
(Snap-N-Spike®)
包装
ampule of 1 mL
制造商/商品名称
Cerilliant®
浓度
2.0 mg/mL (Methanol with 1% 1M HCl)
技术
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
应用
clinical testing
格式
single component solution
储存温度
−20°C
InChI
1S/C35H38Cl2N8O4/c1-3-25(2)45-34(46)44(24-40-45)29-7-5-27(6-8-29)41-14-16-42(17-15-41)28-9-11-30(12-10-28)47-19-31-20-48-35(49-31,21-43-23-38-22-39-43)32-13-4-26(36)18-33(32)37/h4-13,18,22-25,31H,3,14-17,19-21H2,1-2H3/t25?,31-,35-/m0/s1
InChI key
VHVPQPYKVGDNFY-ZPGVKDDISA-N
一般描述
Itraconazole is an antifungal drug prescribed for oral or intravenous treatment of fungal infections. The drug is sold under trade names such as Sporanoxor Onmel®. This Certified Spiking Solution® is suitable as starting material for calibrators, controls, or linearity standards for clinical and diagnostic testing or therapeutic drug monitoring of itraconazole in patient blood, serum, or plasma samples by LC-MS/MS or HPLC.
应用
- Enhanced drug delivery: A study by Soe HMSH et al. discusses a synthetic citric crosslinked beta-cyclodextrin derivative designed to improve the solubility, cytotoxicity, and antifungal activity of drugs like Itraconazole. This innovative approach enhances the bioavailability and therapeutic efficacy of antifungal medications, crucial for treating persistent fungal infections (Soe HMSH et al., 2023).
- Novel formulation techniques: Research by Becelaere J et al. explores solvent electrospinning to create amorphous solid dispersions with high Itraconazole content. This method significantly enhances drug loading and release potential, providing new insights into pharmaceutical formulation and controlled drug delivery systems (Becelaere J et al., 2023).
- Pharmaceutical sciences research: A study by Nunes PD et al. uses in vitro tools to predict the bioavailability of amorphous solid dispersions of drugs like Itraconazole. Their work provides crucial mechanistic insights into drug dissolution and permeation, aiding in the optimization of oral dosage forms for enhanced therapeutic effectiveness (Nunes PD et al., 2023).
- Optimization of sustained release formulations: Research by Wang W et al. on optimizing the O/W emulsion solvent evaporation method for Itraconazole microspheres highlights advancements in sustained-release formulations. This approach aims to improve dosing regimens and patient compliance in chronic treatments (Wang W et al., 2023).
法律信息
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Onmel is a registered trademark of Merz Pharmaceuticals, LLC
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
相关产品
产品编号
说明
价格
警示用语：
Danger
危险分类
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
靶器官
Eyes,Central nervous system
WGK
WGK 2
闪点(°F)
49.5 °F
闪点(°C)
9.7 °C
法规信息
危险化学品
Hiroshi Tsubamoto et al.
Anticancer research, 34(4), 2007-2014 (2014-04-03)
Recurrent ovarian clear cell carcinoma (CCC) rarely responds to cytotoxic agents. Itraconazole is a potent inhibitor of the P-glycoprotein efflux pump, angiogenesis, and the Hedgehog pathway. We evaluated the efficacy of chemotherapy with itraconazole for CCC. Medical charts of patients
Hans Christian Korting et al.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 7(1), 11-19 (2008-05-16)
Itraconazole is an antifungal drug from the triazole group with distinct in vitro activity against dermatophytes, yeasts and some molds. Itraconazole has a primarily fungistatic activity. Itraconazole accumulates in the stratum corneum and in nail material due to its high
Marie Charles et al.
Therapie, 66(2), 103-108 (2011-06-04)
Itraconazole is a triazole antifungal agent that is active against Aspergillus, histoplasmosis, and rare fungal infections. Itraconazole exhibit marked variability in drug concentration as a result of inconsistent absorption, metabolism, or interaction with concomitant medications. Preclinical and clinical data have
[Pharmacological, pharmacokinetic, and clinical profile of itraconazole oral solution (ITRIZOLE Oral Solution 1%)].
Hisaya Otani et al.
Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 130(1), 69-76 (2007-07-20)
James D Homans et al.
The Pediatric infectious disease journal, 29(1), 65-67 (2009-11-04)
Coccidioides immitis causes a wide range of disease in humans. Fluconazole and itraconazole are effective treatments. Clinical evidence suggests that itraconazole is equivalent or superior to fluconazole in treating osteoarticular infections in rates of cure and recurrence. We report 2
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门